Pseudomonas Aeruginosa Infection Treatment Market – Vast Scope of Novel Treatment Approach Shows Way for Growth
The appearance of drug-resistant strains of pseudomonas aeruginosa, leading to high mortality rates, have led to a large number of new approaches for the treatment of the associated infection. So much so, infections due to pseudomonas aeruginosa are now considered a public health concern. Meanwhile, increasing antibacterial drug resistance has necessitated research and innovations in the antibacterial field, in general. According to statistics of the Centers for Disease Control and Prevention, in the U.S., each year, more than 2 million infections and 23,000 deaths are associated with bacterial drug resistance.
To address this issue, enormous research and innovation efforts are underway in the antibacterial field. In particular, for pseudomonas aeruginosa, the development of anti-infectives, new antibiotic formulations, and the antivirulence approach are some of the initiatives taken for the fight against the pathogen. Such needs have risen due to real concerns of hospital-acquired infections associated with pseudomonas aeruginosa, especially among critically-ill and immunocompromised patients.
This has prompted several studies to evaluate the factors for the drug resistance of pseudomonas aeruginosa, and potential consequences on mortality. Besides this, limitations of current therapies, potential for alternative drugs, and new therapeutic options for pseudomonas aeruginosa bode well for the pseudomonas aeruginosa treatment infection market. Transparency Market Research (TMR) has released a market study publication on the pseudomonas aeruginosa treatment infection market. According to the findings of TMR, the pseudomonas aeruginosa treatment infection market is predicted to expand at a notable ~6% CAGR over the forecast period of 2019 to 2027.
However, on the downside, the development of pseudomonas aeruginosa infection treatment faces hindrances as well. Firstly, scientific and technical challenges pertaining to the development of new antibacterial drugs is impeding pharma companies in such pursuits. Besides, the high cost of development of novel antibacterial formulations that are mostly kept in reserve, makes it difficult for companies to recover their investments. Incidence of incorrectly prescribed antibacterial drugs resulting in the rise of resistant bacteria is a bottleneck for the development of pseudomonas aeruginosa infection treatment options.
Identify the key factors that will drive your company’s growth. Request a brochure of this report here
No comments:
Post a Comment